doi:10.3969/j.issn.1673-8640.2015.09.011

Abstract

CLC Number:

R446.11

Figures/Tables 6

References 14

[1]	邱志琦,温少磊,谭智毅.胃蛋白酶原Ⅰ、Ⅱ及其比值在胃癌筛查中的应用[J]. 检验医学与临床,2013,10(14): 1806-1807.
[2]	项文坤,熊锋宝,杨铁一,等.血清唾液酸上皮膜抗原及甘氨酰脯氨酸二肽氨基肽酶单项及联合检测诊断胃癌的临床研究[J]. 中国实用内科杂志,2009,29(11):1012-1014.
[3]	徐光炜. 新编常见恶性肿瘤诊治规范——胃癌分册[M].北京:北京医科大学中国协和医科大学联合出版社,1999:40-47.
[4]	梁军. 血清胃蛋白酶原在胃腺癌诊断中的临床价值[J].全科医学临床与教育,2014,12(3):247-249.
[5]	KAGEYAMA T.Pepsinogens,progastricsins,and prochymosins: structure,function,evolution,and development[J]. Cell Mol Life Sci,2002,59(2):288-306.
[6]	张金锋. 血清胃蛋白酶原、CEA、CA19-9及CA72-4检测对胃癌的诊断价值探讨[J]. 检验医学,2014,29(8): 831-834.
[7]	卢灿荣,张士武,张勇,等. 癌胚抗原、糖链抗原72-4和胃蛋白酶原联合检测评价胃癌的诊断价值[J]. 检验医学,2012,27(6): 442-444.
[8]	费凤英,王金金,祝新华. 血清胃蛋白酶原检测在胃癌诊治中的应用进展[J].医学信息,2011,24(3):1461-1463.
[9]	赵兰静,刘春兴,安仙园. 血清胃蛋白酶原和抗Hp IgG抗体对消化性溃疡的临床意义[J]. 检验医学,2014,29(11): 1124-1127.
[10]	KONTUREK PC,KONTUREK SJ,BRZOZOWSKI T.Helicobacter pylori infection in gastric cancerogenesis[J]. J Physiol Pharmacol,2009,60(3):3-21.
[11]	LORENTE S,DOIZ O,TRINIDAD SERRANO M,et al.Helicobacter pylori stimulates pepsinogen secretion from isolated human peptic cells[J]. Gut,2002,50(1): 13-18.
[12]	SUN LP,GONG YH,WANG L, et al . Serum pepsinogen levels and their influencing factors: a population-based study in 6 990 Chinese from North China[J]. World J Gastroenterol,2007,13( 48): 6562-6567.
[13]	OISHI Y,KIYOHARA Y,KUBO M,et al.The serum pepsinogen test as a predictor of gastric cancer: the Hisayama study[J]. Am J Epidemiol,2006,163(7):629-637.
[14]	赵瑶,刘银梅,胡文斌,等. 胃蛋白酶原在癌前病变、胃癌诊断中的应用进展[J]. 实用癌症杂志,2011,26(2):205-207.

组别	例数	PGⅠ(ng/mL)	PGⅡ(ng/mL)	PGR	GPDA(U/L)
胃癌组	50	67.96±17.24^*#Δ▲▲	25.27±4.63^*#Δ※	2.75±0.86^*#Δ▲▲	54.78±13.16^*#Δ▲▲
慢性萎缩性胃炎组	50	89.22±24.39^*	23.37±4.84^*	4.04±1.41*	65.72±15.26^*
浅表性胃炎组	50	126.50±31.25^Δ▲▲	20.36±7.06^Δ▲	6.43±0.88^Δ▲▲	75.00±11.97^▲▲
胃溃疡组	50	178.22±48.76^*▲▲	31.77±8.78^*▲▲	5.73±1.28^*▲▲	75.34±12.99^▲▲
正常对照组	50	132.44±21.96	20.77±4.42	6.53±1.25	74.88±13.53

组别	例数	PGⅠ(ng/mL)	PGⅡ(ng/mL)	PGR	GPDA(U/L)
胃癌组	50	67.96±17.24^*#Δ▲▲	25.27±4.63^*#Δ※	2.75±0.86^*#Δ▲▲	54.78±13.16^*#Δ▲▲
慢性萎缩性胃炎组	50	89.22±24.39^*	23.37±4.84^*	4.04±1.41*	65.72±15.26^*
浅表性胃炎组	50	126.50±31.25^Δ▲▲	20.36±7.06^Δ▲	6.43±0.88^Δ▲▲	75.00±11.97^▲▲
胃溃疡组	50	178.22±48.76^*▲▲	31.77±8.78^*▲▲	5.73±1.28^*▲▲	75.34±12.99^▲▲
正常对照组	50	132.44±21.96	20.77±4.42	6.53±1.25	74.88±13.53

组别	例数	Hp阳性
组别	例数	阳性例数(%)	PGⅠ(ng/mL)	PGⅡ(ng/mL)		PGR	GPDA(U/L)
胃癌组	50	38(76)	66.37±18.86	24.52±4.71		2.78±0.97	54.16±12.01
浅表性胃炎组	50	34(68)	131.41±28.69	20.99±6.27		6.45±0.97	75.00±11.41
胃溃疡组	50	40(80)	180.28±45.94	31.60±8.76		5.86±1.33	75.80±13.36
慢性萎缩性胃炎组	50	36(72)	86.14±21.66	22.92±4.16		3.99±1.38	65.69±13.48
正常对照组	50	29(58)	132.83±18.59	20.23±3.99		6.75±1.42	75.28±13.40
组别	例数	Hp阴性
组别	例数	阴性例数(%)	PGⅠ(ng/mL)	PGⅡ(ng/mL)	PGR			GPDA(U/L)
胃癌组	50	12(24)	73.00±9.51	27.67±3.57	2.66±0.34		56.75±16.65
浅表性胃炎组	50	16(32)	116.06±34.74	19.03±8.58	6.38±0.70		75.00±13.49
胃溃疡组	50	10(20)	170.01±60.90	32.48±9.31	5.21±0.93		73.50±11.85
慢性萎缩性胃炎组	50	14(28)	97.14±29.75	24.53±6.30	4.16±1.51		67.14±19.26
正常对照组	50	21(42)	131.90±26.41	21.52±4.96	6.22±0.91		74.33±14.03

组别	例数	Hp阳性
组别	例数	阳性例数(%)	PGⅠ(ng/mL)	PGⅡ(ng/mL)		PGR	GPDA(U/L)
胃癌组	50	38(76)	66.37±18.86	24.52±4.71		2.78±0.97	54.16±12.01
浅表性胃炎组	50	34(68)	131.41±28.69	20.99±6.27		6.45±0.97	75.00±11.41
胃溃疡组	50	40(80)	180.28±45.94	31.60±8.76		5.86±1.33	75.80±13.36
慢性萎缩性胃炎组	50	36(72)	86.14±21.66	22.92±4.16		3.99±1.38	65.69±13.48
正常对照组	50	29(58)	132.83±18.59	20.23±3.99		6.75±1.42	75.28±13.40
组别	例数	Hp阴性
组别	例数	阴性例数(%)	PGⅠ(ng/mL)	PGⅡ(ng/mL)	PGR			GPDA(U/L)
胃癌组	50	12(24)	73.00±9.51	27.67±3.57	2.66±0.34		56.75±16.65
浅表性胃炎组	50	16(32)	116.06±34.74	19.03±8.58	6.38±0.70		75.00±13.49
胃溃疡组	50	10(20)	170.01±60.90	32.48±9.31	5.21±0.93		73.50±11.85
慢性萎缩性胃炎组	50	14(28)	97.14±29.75	24.53±6.30	4.16±1.51		67.14±19.26
正常对照组	50	21(42)	131.90±26.41	21.52±4.96	6.22±0.91		74.33±14.03

项目	最佳临界值	灵敏度(%)	特异度(%)	阳性预测值(%)	阴性预测值(%)
PGⅠ	80.50 ng/mL	66.00	76.00	70.37	73.91
PGⅡ	25.70 ng/mL	32.00	50.00	60.98	57.63
PGR	3.28	72.00	90.00	76.27	87.80
GPDA	57.50 U/L	72.00	62.00	68.89	65.45

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 6

References 14

Related Articles 15

Recommended Articles

Metrics

项目	AUC	标准误	P值	95%可信区间
PGⅠ	0.763	0.048	0.000	0.669~0.857
PGⅡ	0.397	0.056	0.075	0.286~0.507
PGR	0.801	0.046	0.000	0.710~0.892
GPDA	0. 715	0.052	0.000	0.613~0.817

项目	灵敏度	特异度	阳性预测值	阴性预测值
PGⅠ并联PGR	86.00	76.00	78.18	73.33
PGⅠ并联GPDA	76.00	70.00	76.74	61.40
PGR并联GPDA	84.00	78.00	77.78	82.61
PGⅠ并联PGR并联GPDA	92.00	72.00	85.19	78.26

[1]	LI Li, SHI Huaying, Zaxiyangzong , Dawazhuoma , CHEN Yanmei, YANG Chunjiao, WEN Honglin. Application of indirect method in establishing reference range of adult blood lipids in Lhasa [J]. Laboratory Medicine, 2025, 40(11): 1064-1069.
[2]	SHEN Zhiying, CHEN Ming, DONG Yueying. Correlation between serum Hcy，S100B levels and cerebral metabolite indicators and cognitive impairment in elderly AIS patients [J]. Laboratory Medicine, 2025, 40(11): 1097-1101.
[3]	CHEN Wenli, JIN Cheng, ZHOU Lulu, XU Weiyi. Role of MicroR in guiding platelet count re-examination [J]. Laboratory Medicine, 2025, 40(9): 897-900.
[4]	WANG Qiuju, XIAO Huijian, WU Shuang, ZHAO Wanting, DAI Xubo, ZHUANG Yuepeng. Role of peripheral blood lymphocyte morphological classification in curative effect judgment of critical influenza [J]. Laboratory Medicine, 2025, 40(9): 901-906.
[5]	ZHANG Hui, YUAN Jingwen, ZHANG Chi. Adult reference ranges for platelet count and platelet-related parameters using fluorescence method in Wuhan [J]. Laboratory Medicine, 2025, 40(9): 892-896.
[6]	SHI Shaoxin, CHEN Xueting, XU Xiaofeng, LU Renquan, GUO Lin, ZHUANG Yihui. Role of coagulation function in bacterial bloodstream infection among malignant tumor patients [J]. Laboratory Medicine, 2025, 40(8): 804-809.
[7]	JIANG Fengying, JIANG Yun, MI Rui, QIAN Ximing, WANG Qiubo. Changes of platelet and coagulation function indicators in elderly patients with diabetic foot ulcers [J]. Laboratory Medicine, 2025, 40(7): 708-712.
[8]	YAO Lifeng, ZHANG Ling. Research progress on clinical significance of monocyte distribution width in infection and inflammatory diseases [J]. Laboratory Medicine, 2025, 40(5): 503-507.
[9]	DAI Jingwen, YANG Shuo, WANG Chong, SUN Lin, GU Meixiu, XIAN Jingrong, PAN Baishen, WANG Beili, ZHANG Chunyan, GUO Wei. Role of preoperative mean corpuscular hemoglobin concentration for predicting postoperative recurrence in intrahepatic cholangiocarcinoma patients [J]. Laboratory Medicine, 2025, 40(4): 344-349.
[10]	ZHANG Haoyang, LU Lin, ZONG Ming, HE Long, DING Yuanyuan, FAN Lieying. Diagnostic and predictive value of white blood cell population data in patients with sepsis [J]. Laboratory Medicine, 2025, 40(3): 271-277.
[11]	ZHOU Jiakuan, GUO Ping, CAI Qi, YANG Mingkang, HUANG Zhixi, XUE Yilun, HUA Renxiang, LIN Han, LI Jiaming, WANG Jianbiao. Molecular epidemiological analysis of patients with increased stomatocytes and giant platelets in peripheral blood [J]. Laboratory Medicine, 2025, 40(2): 171-177.
[12]	WANG Chengyun, GU Ping, PAN Qiuhui, WANG Jing. Changes and clinical value of blood coagulation indexes in children with infection [J]. Laboratory Medicine, 2025, 40(2): 178-181.
[13]	. [J]. Laboratory Medicine, 2025, 40(2): 197-200.
[14]	ZHANG Lan, ZHU Jianfeng, PAN Baishen, CHEN Pu, WANG Beili, GUO Wei. Prognostic value of circulating plasma cells determined by morphology in newly diagnosed multiple myeloma [J]. Laboratory Medicine, 2025, 40(1): 15-19.
[15]	CUI Weiqi, OU Xinyang, ZHAO Chunhe, XIA Wei, QU Linlin. Progress of thrombin-activatable fibrinolysis inhibitor determination in clinical application [J]. Laboratory Medicine, 2024, 39(10): 1021-1026.